Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development
Actelion Pharmaceuticals Ltd
Akaal Pharma Pty Ltd
Are Pharmaceuticals Inc
Astellas Pharma Inc
Beijing Foreland Pharma Co Ltd
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Curadim Pharma Co Ltd
GlaxoSmithKline Plc
Idorsia Pharmaceutical Ltd
LG Chem Ltd
Mebias Discovery LLC
Mitsubishi Tabe Pharma Corp
Novartis AG
Oppilan Pharma Ltd
Sun Pharma Advanced Research Company Ltd
Suzhou Connect Biopharmaceuticals Ltd
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles
AK-119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKP-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amiselimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-4058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Actelion Pharmaceuticals Ltd, H2 2019
Pipeline by Akaal Pharma Pty Ltd, H2 2019
Pipeline by Arena Pharmaceuticals Inc, H2 2019
Pipeline by Astellas Pharma Inc, H2 2019
Pipeline by Beijing Foreland Pharma Co Ltd, H2 2019
Pipeline by Boston Pharmaceuticals Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Curadim Pharma Co Ltd, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Pipeline by LG Chem Ltd, H2 2019
Pipeline by Mebias Discovery LLC, H2 2019
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Oppilan Pharma Ltd, H2 2019
Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Discontinued Products, H2 2019